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ABSTRACT 29 
 30 
SOX2 positive pituitary stem cells (PSCs) are specified embryonically and persist 31 
throughout life, giving rise to all pituitary endocrine lineages. We have previously 32 
shown the activation of the STK/LATS/YAP/TAZ signalling cascade in the 33 
developing and postnatal mammalian pituitary. Here, we investigate the function of 34 
this pathway during pituitary development and in the regulation of the SOX2 cell 35 
compartment. Through loss- and gain-of-function genetic approaches, we reveal that 36 
restricting YAP/TAZ activation during development is essential for normal organ size 37 
and specification from SOX2+ PSCs.  Postnatal deletion of LATS kinases and 38 
subsequent upregulation of YAP/TAZ leads to uncontrolled clonal expansion of the 39 
SOX2+ PSCs and disruption of their differentiation, causing the formation of non-40 
secreting, aggressive pituitary tumours. In contrast, sustained expression of YAP 41 
alone results in expansion of SOX2+ PSCs capable of differentiation and devoid of 42 
tumourigenic potential. Our findings identify the LATS/YAP/TAZ signalling cascade 43 
as an essential component of PSC regulation in normal pituitary physiology and 44 
tumourigenesis. 45 
 46 
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INTRODUCTION 59 
 60 
SOX2 is crucial transcription factor involved in the specification and maintenance of 61 
multiple stem cell populations in mammals. Pituitary stem cells express SOX2 and 62 
contribute to the generation of new endocrine cells during embryonic development 63 
and throughout postnatal life1, 2. The pituitary gland is composed of three parts, the 64 
anterior, intermediate and posterior lobes (AL, IL and PL, respectively). The AL and 65 
IL contain hormone-secreting cells, which are derived from an evagination of the oral 66 
ectoderm expressing SOX2, termed Rathke’s pouch (RP). SOX2+ cells, both in the 67 
embryonic and adult pituitary, can differentiate into three endocrine cell lineages, 68 
which are marked by transcription factors PIT1 (POU1F1)3, TPIT (TBX19)4 and SF1 69 
(NR5A1)5, and differentiate into hormone-secreting cells (somatotrophs, lactotrophs, 70 
thyrotrophs, corticotrophs, melanotrophs and gonadotrophs, which express growth 71 
hormone, prolactin, thyrotropin, adrenocorticotropin, melanotropin and gonadotropin, 72 
respectively). SOX2+ PSCs are highly proliferative during the first 2-3 weeks of life, 73 
in concordance with major organ growth, after which they reach a steady low 74 
proliferative capacity that contributes to maintain normal homeostasis and 75 
physiological adaptation of the pituitary gland6, 7.  76 
 77 
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Contrary to other organs, where somatic stem cells are shown to be able to become 78 
transformed into cancer stem cells, the roles of SOX2+ PSCs in tumourigenesis 79 
remain poorly understood, possibly due to the patchy knowledge of the pathways 80 
regulating SOX2+ PSC fate and proliferation. Pituitary tumours are common in the 81 
population, representing 10-15% of all intracranial neoplasms8, 9. Adenomas are the 82 
most common adult pituitary tumours, classified into functioning, when they secrete 83 
one or more of the pituitary hormones, or non-functioning if they do not secrete 84 
hormones. In children, adamantinomatous craniopharyngioma (ACP) is the most 85 
common pituitary tumour. Targeting oncogenic beta-catenin in SOX2+ PSCs in the 86 
mouse generates clusters of senescent SOX2+ cells that induce tumours resembling 87 
ACP in a paracrine manner, i.e. the tumours do not derive from the targeted SOX2+ 88 
PSCs1, 10. Up to 15% of adenomas and 50% of ACP display aggressive behaviour 89 
with invasion of nearby structures including the hypothalamus and visual tracts, 90 
associated with significant morbidity and mortality11. Pituitary carcinomas exhibiting 91 
metastasis are rare but can develop from benign tumours12, 13, 14. Whether SOX2+ 92 
cells can cell autonomously contribute to pituitary neoplasia has not been hitherto 93 
demonstrated. 94 
 95 
The Hippo pathway controls stem cell proliferation and tumourigenesis in several 96 
organs such as in the liver15, 16, intestines17 and lung18, 19. In the core phosphorylation 97 
cascade, STK3/4 kinases phosphorylate and activate LATS1/2 serine/threonine-98 
protein kinases, which in turn phosphorylate co-activators Yes-associated protein 99 
(YAP1, a.k.a. YAP) and WW domain-containing transcription regulator protein 1 100 
(WWTR1, a.k.a. TAZ) that are subsequently inactivated through degradation and 101 
cytoplasmic retention20. Active YAP/TAZ associate with TEAD transcription factors, 102 
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promoting the transcription of target genes such as Cyr61 and Ctgf 21, 22, 23. YAP/TAZ 103 
have been shown to promote proliferation and the stem cell state in several organs, 104 
and can also lead to transformation and tumour initiation when overexpressed24, 25, 26.  105 
The involvement of YAP/TAZ in the function of tissue-specific SOX2+ stem cells 106 
during development and homeostasis has not been shown. We previously reported 107 
strong nuclear localisation of YAP and TAZ exclusively in SOX2+ stem cells of 108 
developing Rathke's pouch and the postnatal anterior pituitary of mice and humans, 109 
and enhanced expression in human pituitary tumours composed of uncommitted cells, 110 
including ACPs and null-cell adenomas27, 28, which do not express any of the lineage 111 
transcription factors PIT1, TPIT or SF1. In these populations we detected 112 
phosphorylation of YAP at serine 127 (S127) indicating LATS kinase activity. 113 
Together these point to a possible function for LATS/YAP/TAZ in normal pituitary 114 
stem cells and during tumourigenesis. Here, we have combined genetic and molecular 115 
approaches to reveal that deregulation of the pathway can promote and maintain the 116 
SOX2+ PSC fate under physiological conditions and that major disruption of this axis 117 
transforms SOX2+ PSCs into cancer-initiating cells giving rise to aggressive tumours.     118 
 119 
RESULTS 120 
 121 
Sustained conditional expression of YAP during development promotes SOX2+ 122 
PSC fate  123 
To determine if YAP and TAZ function during embryonic development of the 124 
pituitary, we used genetic approaches to perform gain- and loss-of-function 125 
experiments. We first expressed a constitutive active form of YAP(S127A) using the 126 
Hesx1-Cre driver, which drives Cre expression in Rathke’s pouch (RP) and the 127 
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hypothalamic primordium from 9.5dpc, regulated by administration of doxycycline 128 
through the reverse tetracycline-dependent transactivator (rtTA) system (R26rtTA/+; see 129 
Methods for details, Scheme Fig1A). Analyses were restricted to embryonic time 130 
points. As expected, we confirmed accumulation of total YAP protein but not of TAZ 131 
or pYAP(S127), throughout the developing pituitary and hypothalamus of 132 
Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ (hereafter YAP-TetO) embryos at 15.5dpc, but 133 
not of Cre-negative controls (Fig1B, Figure 1 – figure supplement 1A). Likewise, the 134 
YAP downstream target Cyr61 (Fig1B) was also upregulated. Morphologically, YAP-135 
TetO mutants displayed a dysplastic anterior pituitary, which was more medially 136 
compacted and lacked a central lumen, making it difficult to distinguish between the 137 
developing anterior and intermediate lobes (Fig 1C). Immunofluorescence staining 138 
against SOX2 at 15.5dpc demonstrated loss of SOX2 in the most lateral regions of 139 
control pituitaries (arrows in Fig. 1C), where cells are undergoing commitment; yet 140 
mutant pituitaries had abundant SOX2 positive cells in the most lateral regions 141 
(arrowheads in Fig1C). Immunostaining for LHX3, which is expressed in the 142 
developing anterior pituitary29, was used to demarcate AL and IL tissue. Staining 143 
using antibodies against lineage markers PIT1, TPIT and SF1 revealed a concomitant 144 
reduction in committed cell lineages throughout the gland (Fig1D; PIT1 0.35% in 145 
mutants compared with 30.21% in controls (Student’s t-test P<0.0001, n=3 for each 146 
genotype), TPIT 1.03% in mutants compared with 9.81% in controls (Student’s t-test 147 
P=0.0012, n=3 for each genotype), SF1 0.34% in mutants compared with 4.14% in 148 
controls (Student’s t-test P=0.0021, n=3 for each genotype)). We therefore conclude 149 
that sustained activation of YAP prevents lineage commitment and is sufficient to 150 
maintain the progenitor state during embryonic development.  151 
 152 
 7 
We did not obtain any live Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ pups at birth when 153 
treated with doxycycline from 5.5dpc (n=5 litters). To bypass the embryonic lethality 154 
of these early inductions, we commenced doxycycline treatment from 9.5dpc, the 155 
onset of RP formation (Figure 1 – figure supplement 1B). 156 
Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ pups were viable and were maintained on 157 
doxycycline until P24, at which point the experimental end point was reached due 158 
to excessive weight loss and animals had to be culled following UK Home Office 159 
Regulations. Histological analyses of pituitaries revealed multiple anterior lobe cysts 160 
per gland, localising predominantly in the ventral AL (n=4) (Figure 1 – figure 161 
supplement 1C). These structures developed in YAP-accumulating regions and were 162 
lined by SOX2+ cells (Figure 1 – figure supplement 1D). The proportion of SOX2+ 163 
cells throughout the AL was increased, as was the percentage of SF1+ cells, whereas 164 
PIT1+ cell numbers were significantly decreased and the TPIT lineage, identified by 165 
ACTH antibody staining, was unaffected (Figure 1 – figure supplement 1E). The total 166 
number of cycling Ki-67+ cells showed a trend towards a decrease 167 
in Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ mutants relative to controls, which did not 168 
reach significance (Figure 1 – figure supplement 1F). The cystic structures observed 169 
in Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ mutants were reminiscent of  Rathke’s cleft 170 
cyst (RCC), which is a benign developmental anomaly of the pituitary characterised 171 
by the presence of ciliated and secretory cells, expression cytokeratins and frequent 172 
expression of p63. Immunostaining revealed that cysts were lined by cytokeratin+ 173 
cells using the AE1/AE3 pan-cytokeratin cocktail and basal cells were positive for 174 
nuclear p63 in Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ mutant pituitaries (Figure 1 – 175 
figure supplement 1G). Staining using antibodies against ARL13B and Acetylated D-176 
Tubulin (Lys40) marking cilia, revealed multi-ciliated cells along the cyst lining 177 
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(Figure 1 – figure supplement 1H). Combined staining using Alcian Blue and the 178 
Periodic Acid-Schiff technique (AB/PAS) to recognise mucins, detected royal blue-179 
stained mucous cells lining the cysts (Figure 1 – figure supplement 1H). Taken 180 
together, we conclude that sustained activation of YAP during embryonic and 181 
postnatal pituitary development, promotes maintenance and abnormal expansion of 182 
SOX2+ epithelia during development, resulting in the formation of cysts that 183 
resemble RCC. 184 
 185 
Next, we generated embryos null for TAZ and conditionally lacking YAP in the 186 
Hesx1 expression domain (Figure 1 – figure supplement 2A-E). 187 
Hesx1Cre/+;Yapfl/fl;Taz-l- double mutants were obtained at expected ratios during 188 
embryonic stages until 15.5dpc, however the majority of Taz-/- mutants with or 189 
without compound Yap deletions showed lethality at later embryonic and early 190 
postnatal stages30 (Supplementary File 1). The developing pituitary gland of 191 
Hesx1Cre/+;Yapfl/fl;Taz-l-  double mutants appeared largely normal at 13.5dpc by 192 
histology (Figure 1 – figure supplement 2A). Immunostaining against SOX2 to mark 193 
embryonic progenitors and postnatal stem cells did not reveal differences in the 194 
spatial distribution of SOX2+ cells between double mutants compared to controls 195 
(Hesx1+/+;Yapfl/fl;Taz+/+ and Hesx1+/+;Yapfl/fl;Taz+/-) at 13.5dpc, 16.0dpc (Figure 1 – 196 
figure supplement 2B) or P28, even in regions devoid of both TAZ and active YAP 197 
(Figure 1 – figure supplement 2C,D). This suggests that YAP/TAZ are not required 198 
for SOX2+ cell specification or survival. Likewise, analysis of commitment markers 199 
PIT1and SF1 as well as ACTH to identify the TPIT lineage, did not show any 200 
differences between genotypes (Figure 1 – figure supplement 2E). Together, these 201 
data suggest there is no critical requirement for YAP and TAZ during development 202 
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for the specification of SOX2+ cells or lineage commitment, but that YAP functions 203 
to promote the SOX2 cell identity.  204 
 205 
LATS, but not STK, kinases are required for normal pituitary development and 206 
differentiation  207 
Since sustained activation of YAP led to an embryonic phenotype, we reasoned that 208 
YAP/TAZ need to be regulated during embryonic development. To determine if STK 209 
and LATS kinases are important in YAP/TAZ regulation we carried out genetic 210 
deletions in the pituitary.  211 
 212 
Conditional deletion of Stk3 and Stk4 (also called Mst2 and Mst1) in 213 
Hesx1Cre/+;Stk3fl/fl;Stk4fl/fl embryos did not lead to a pituitary phenotype (Figure 2 – 214 
figure supplement 1). A reduction of over 75% in total STK3/4 proteins in mutants 215 
was confirmed by western blot on total lysates from Stk3fl/fl;Stk4fl/fl controls and  216 
Hesx1Cre/+;Stk3fl/fl;Stk4fl/fl  mutants (Figure 2 – figure supplement 1B). Mutant 217 
pituitaries were macroscopically normal at birth (Figure 2 – figure supplement 1A), 218 
and showed comparable expression patterns of TAZ, YAP, pYAP to controls lacking 219 
Cre, without distinct accumulation of YAP or TAZ (Figure 2 – figure supplement 220 
1C). The distribution of SOX2+ cells was comparable between mutants and controls 221 
(Figure 2 – figure supplement 1C). Normal lineage commitment was evident by 222 
immunofluorescence staining for PIT1, TPIT and SF1 at P10 (Figure 2 – figure 223 
supplement 1D). Mutant animals remained healthy and fertile until P70, at which 224 
point pituitaries appeared histologically normal (Figure 2 – figure supplement 1E). 225 
Since deletion of Stk3/4 at embryonic stages does not affect embryonic or postnatal 226 
pituitary development, we conclude these kinases are not critical for YAP/TAZ 227 
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regulation in the pituitary. 228 
 229 
We next focused on perturbing LATS kinase function, as we have previously shown 230 
strong expression of Lats1 in the developing pituitary and postnatal kinase activity in 231 
SOX2+ stem cells27. However, Hesx1Cre/+;Lats1fl/fl embryos showed unaffected 232 
pituitary development and normal localisation and levels of YAP and TAZ as 233 
assessed by immunofluorescence (Figure 2 – figure supplement 2A,B) when 234 
compared with controls. mRNA in situ hybridisation against Lats2 at P2, revealed 235 
abundant Lats2 transcripts upon conditional deletion of Lats1, suggesting a 236 
compensatory upregulation of Lats2 in the absence of LATS1 (Figure 2 – figure 237 
supplement 2C), similar to previous reports of elevated YAP/TAZ signalling inducing 238 
Lats2 expression31.  239 
 240 
To overcome potential functional redundancy, we deleted both Lats1 and Lats2 in RP. 241 
Deletion of Lats2 alone (Hesx1Cre/+;Lats2fl/fl), did not reveal any developmental 242 
morphological anomalies (Figure 2 – figure supplement 2D) and pups were identified 243 
at normal Mendelian proportions (Supplementary File 2).  Similarly, deletion of any 244 
three out of four Lats alleles did not affect pituitary development and were identified 245 
at normal ratios, similar to other tissues32. Homozygous Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl 246 
mutants were identified at embryonic stages at reduced Mendelian ratios and were 247 
absent at P0-P2, suggesting embryonic and perinatal lethality (Supplementary File 2).  248 
 249 
Haematoxylin/eosin staining of the developing pituitary gland in 250 
Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl mutants revealed overgrowth of RP by 13.5dpc compared 251 
to controls lacking Cre (Fig2A, n=4).  Total TAZ and YAP proteins accumulated 252 
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throughout the developing gland in double mutants (arrowheads) but only in the 253 
SOX2+ periluminal epithelium of controls (arrows). The same regions showed a 254 
marked reduction in pYAP-S127 staining, which is observed in SOX2+ cells of the 255 
control (Fig2A). These findings are in line with LATS1/2 normally regulating YAP 256 
and TAZ in the pituitary and demonstrate successful deletion in RP. The mutant 257 
pituitary was highly proliferative (Fig2B, Figure 2 – figure supplement 2F; Ki-67 258 
index average 47.42% ±1.73 SEM in control versus 76.04% ±9.11 SEM in the double 259 
mutant, P=0.0067, Student’s t-test) and the majority of cells expressed SOX2 260 
(Fig2A,C) but not SOX9 (Fig2B, Figure 2 – figure supplement 2F).  261 
 262 
By 15.5dpc the pituitary was grossly enlarged and exerting a mass effect on the brain, 263 
had cysts and displayed areas of necrosis (asterisks Fig2, Figure 2 – figure 264 
supplement 2E, n=5). Staining for Endomucin to mark blood vessels revealed poor 265 
vascularisation in Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl mutants compared to the ample 266 
capillaries seen in the control (Fig2C), which may account for the necrosis. This could 267 
be due to a direct inhibition of vascularisation or a consequence of the rapid growth of 268 
this embryonic tumour. We frequently observed ectopic residual pituitary tissue at 269 
more caudal levels, reaching the oral epithelium and likely interfering with 270 
appropriate fusion of the sphenoid, similar to other phenotypes involving pituitary 271 
enlargement (arrows Fig2C)33, 34, 35. Immunofluorescence to detect active (non-272 
phosphorylated) YAP revealed abundant staining throughout the pituitary at 15.5dpc, 273 
compared to the control where active YAP localises in the SOX2 epithelium (Fig2C). 274 
Immunofluorescence using specific antibodies against lineage commitment markers 275 
PIT1, TPIT and SF1 at 15.5dpc revealed very few cells expressing PIT1, TPIT and 276 
SF1 in the double mutant (Fig2D; PIT1 9.14% in mutants compared with 51.4% in 277 
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controls (Student’s t-test P<0.0001); TPIT 4.0% in mutants compared with 11.4% in 278 
controls (Student’s t-test P<0.007); SF1 2.1% in mutants compared with 6.5% in 279 
controls (Student’s t-test P>0.05) n=3 mutants and 5 controls), suggesting failure to 280 
commit into the three lineages. These data suggest that the LATS/YAP/TAZ axis is 281 
required for normal embryonic development of the anterior pituitary and that 282 
LATS1/2 kinases control proliferation of SOX2+ progenitors and their progression 283 
into the three committed lineages. 284 
 285 
Loss of LATS kinases results in carcinoma-like murine tumours 286 
Postnatal analysis of Hesx1Cre/+;Lats1fl/fl pituitaries revealed that by P56, despite 287 
developing normally during the embryonic period, all glands examined exhibited 288 
lesions of abnormal morphology consisting of overgrowths, densely packed nuclei 289 
and loss of normal acinar architecture (n=15). To minimise the likely redundancy by 290 
LATS2 seen at embryonic stages, we generated Lats1 mutants additionally 291 
haploinsufficient for Lats2 (Hesx1Cre/+;Lats1fl/fl;Lats2fl/+). These pituitaries also 292 
developed identifiable lesions accumulating YAP and TAZ (Figure 3 – figure 293 
supplement 1A), which were observed at earlier time points (P21 n=4), the earliest 294 
being 10 days, indicating increased severity. The number of lesions observed per 295 
animal was similar between the two models at P56 (3-8 per animal). Deletion of Lats2 296 
alone (Hesx1Cre/+;Lats2fl/fl), which is barely expressed in the wild type pituitary, did 297 
not result in any defects (Figure 3 – figure supplement 1B). We focused on the 298 
Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ double mutants for further analyses. 299 
 300 
Histological examination of Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ pituitaries confirmed the 301 
abnormal lesions were tumours, characterised by frequent mitoses, focal necrosis, and 302 
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a focal squamous differentiation, as well as the occasional presence of cysts (Fig3A). 303 
These lesions were identical to those in Hesx1Cre/+;Lats1fl/fl pituitaries (not shown). 304 
These tumours accumulated YAP/TAZ and upregulated expression of targets Cyr61 305 
and Ctgf (Fig3B), confirming the validity of the genetic manipulation (Fig3B). 306 
Tumours were also frequently observed in the anterior and intermediate lobe (Figure 307 
3 – figure supplement 1C). Analysis of proliferation by Ki-67 immunostaining 308 
revealed an elevated mitotic index of 7-28% in tumours (mean 15.46, SEM ±2.74), 309 
compared to 2.97% (SEM ±1.2) mean in control pituitaries not carrying the Lats1 310 
deletion (Fig3C).  311 
In keeping with the morphological evidence of epithelial differentiation (Fig3A), the 312 
tumours were positive for cytokeratins using AE1/AE3 (multiple keratin cocktail) 313 
(Figure 3 – figure supplement 1E). Furthermore, the tumours showed focal 314 
morphological evidence of squamous differentiation and showed positive nuclear p63 315 
staining, frequently expressed in squamous carcinomas (Figure 3 – figure supplement 316 
1E). In contrast, the tumours did not show immunohistochemical evidence of 317 
adenomas i.e. negative for neuroendocrine markers, which all types of adenomas are 318 
typically positive for: the neuroendocrine marker synaptophysin and neuron-specific 319 
enolase (Figure 3  – figure supplement 1F). The lesions were also negative for 320 
chromogranin A, a neuroendocrine granule marker often expressed in clinically non-321 
functioning pituitary adenomas. Tumours were also negative for vimentin, expressed 322 
by spindle cell oncocytoma, an uncommitted posterior pituitary tumour (Figure 3 – 323 
figure supplement 1F). Moreover, immunostaining against PIT1, TPIT and SF1 324 
showed only sparse positive cells within the lesions, suggesting lack of commitment 325 
into endocrine precursors and supporting the undifferentiated nature of the tumour 326 
cells (Fig3D).  Consistent with a tumourigenic phenotype, and role for LATS1 327 
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genomic stabilisation36, staining for gamma-H2A.X detected elevated DNA damage 328 
in cells of the mutant pituitaries compared with controls (Figure 3 – figure supplement 329 
1D). The absence of adenoma or oncocytoma markers together with the histological 330 
appearance, observation of focal necrosis and a high mitotic index support the 331 
features of squamous carcinoma. 332 
 333 
SOX2 +ve cells are the cell of origin of the tumours 334 
Tumour regions were mostly composed of SOX2 positive cells, a sub-population of 335 
which also expressed SOX9 (Fig3E, Figure 3 - figure supplement 1A; 85-97% of 336 
cells, 7 tumours across 4 pituitaries). Close examination of the marginal zone 337 
epithelium, a major SOX2+ stem cell niche of the pituitary, revealed a frequent 338 
‘ruffling’ resembling crypts, likely generated through over-proliferation of the 339 
epithelial stem cell compartment (Fig3F). To determine if the cell of origin of the 340 
tumourigenic lesions is a deregulated SOX2+ stem cell, we carried our specific 341 
deletion of LATS1/2 in postnatal SOX2+ cells using the tamoxifen-inducible Sox2-342 
CreERT2 driver, combined with conditional expression of membrane-GFP in targeted 343 
cells (Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+;R26mTmG/+). 344 
 345 
Tamoxifen induction at P5 or P21, led to abnormal lesions in the anterior pituitary 346 
within three months in all cases. We focused our analyses on inductions performed at 347 
P5, from which time point all animals developed lesions by P35 (Fig4A). Similar to 348 
observations in Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ animals, these areas strongly accumulated 349 
YAP and TAZ (Fig4B), activated expression of targets Cyr61 and Ctgf, displayed 350 
ruffling of the AL epithelium (Fig4C, Figure 4 – figure supplement 1E) and lacked 351 
lineage commitment markers (Fig4D, Figure 4 – figure supplement 1A). These 352 
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lesions showed a similar marker profile to Hesx1-Cre-targeted tumours, with positive 353 
p63 and AE1/AE3 staining (Figure 4 – figure supplement 1B). Lineage tracing 354 
confirmed expression of membrane GFP in tumourigenic lesions, characterised by the 355 
accumulation of YAP and expansion of SOX2+ cells, suggesting they were solely 356 
derived from SOX2+ cells (Fig4E, Figure 4 – figure supplement 1C). Taken together, 357 
our data support that LATS kinase activity is required to regulate the pituitary stem 358 
cell compartment. Loss of LATS1 is sufficient to drive deregulation of SOX2+ 359 
pituitary stem cells, generating highly proliferative non-functioning tumours with 360 
features of carcinomas. 361 
 362 
YAP expression is sufficient to activate pituitary stem cells. 363 
Conditional deletion of LATS1/2 kinases in the pituitary has revealed how these 364 
promote an expansion of SOX2+ve stem cells in the embryonic and postnatal gland at 365 
the expense of differentiation. To establish if this effect was mediated through YAP 366 
alone, we used the tetracycline-controlled conditional YAP-TetO system to promote 367 
YAP (S127A) protein levels in postnatal pituitaries of Hesx1Cre/+;R26rtTA/+;Col1a1tetO-368 
Yap/+ mice. We treated YAP-TetO animals with doxycycline from P21 to P105 (12 369 
week treatment, Fig5A). We did not observe the formation of tumours at any stage 370 
analysed (n=12, Figure 5 – figure supplement 1A). Similarly, we did not observe the 371 
formation of lesions when treating from P5. This is in contrast with the unequivocal 372 
tumour formation observed in Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ mice. Elevation of YAP 373 
protein levels was confirmed following three weeks of doxycycline treatment (P42), 374 
displaying patchy accumulation, likely a result of genetic recombination efficiencies 375 
(Fig5B). Consistent with pathway activation, there was robust elevation in the 376 
expression of transcriptional targets Cyr61 and Ctgf following treatment (Figure 5 – 377 
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figure supplement 1B), however at significantly lower levels compared to 378 
Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ deletions (Figure 5 – figure supplement 1E), and there 379 
was no elevation in phosphorylated inactive YAP (Fig5B). 380 
 381 
Immunofluorescence against SOX2 demonstrated a significant increase in the number 382 
of SOX2+ cells as a proportion of the anterior pituitary (Fig5B,F; 18.0% compared to 383 
12.1% in controls, P=0.0014), a finding recapitulated by SOX9 that marks a subset of 384 
the SOX2 population (Fig5B). This increase in the percentage of SOX2+ cells was 385 
maintained at all stages analysed (Fig5F) and did not affect the overall morphology of 386 
the pituitary. At P42 we observed a significant increase in proliferation among the 387 
SOX2+ pituitary stem cells from 3% in controls to 15% in mutants (P=0.027). 388 
SOX2+ cells make up 10% of all cycling cells (Ki-67%) in normal pituitaries, 389 
however in mutants this increased to 25%, suggesting a preferential expansion of the 390 
SOX2+ population, rather than an overall increase in proliferation (Fig5C).  No 391 
additional marked differences were observed in samples analysed at P63 (6 weeks of 392 
treatment, n=3), however longer treatment (P21 to P105) resulted in sporadic regions 393 
of expanded SOX2+ cells (Figure 5 – figure supplement 1C). These regions did not 394 
express the commitment marker PIT1 and were identifiable by haematoxylin/eosin 395 
staining. In contrast to tumour lesions generated following loss of LATS kinases, 396 
these were not proliferative, were positive for pYAP and did not accumulate high 397 
levels of YAP/TAZ (n=6 lesions). Together these results suggest that the sustained 398 
expression of constitutive active YAP can activate the proliferation of SOX2 stem 399 
cells, but in contrast to deletion of LATS1, this alone is not oncogenic.  400 
 401 
To establish if the expansion of pituitary stem cells following forced expression of 402 
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YAP is reversible, we administered doxycycline to YAP-TetO animals for three 403 
weeks (P21 to P42) by which point there is a robust response, followed by 404 
doxycycline withdrawal for three weeks (until P63) to allow sufficient time for YAP 405 
levels to return to normal (scheme Fig5D). Immunofluorescence against total YAP 406 
protein confirmed restoration of the normal YAP expression pattern and levels after 407 
recovery (Fig5E), and mRNA in situ hybridisation detected a reduction in expression 408 
of YAP/TAZ targets Cyr61 and Ctgf (Figure 5 – figure supplement 1D). Following 409 
recovery from high levels of YAP, the number of SOX2+ cells reduced to comparable 410 
levels as in controls (around 10% of the total anterior pituitary) (Fig5E,F). This 411 
suggests that the effects of YAP overexpression on the stem cell population are 412 
transient following three weeks of treatment (Fig5F). 413 
 414 
Finally, to determine if SOX2+ cells could differentiate into hormone-producing cells 415 
after the reduction in YAP levels, we expressed constitutive active YAP only in 416 
SOX2+ cells whilst lineage tracing this population 417 
(Sox2CreERT2/+;R26rtTA/mTmG;Col1a1tetO-Yap/+). We induced SOX2+ cells by low-dose 418 
tamoxifen administration at P21 and treated with doxycycline for three weeks, 419 
followed by doxycycline withdrawal for a further three weeks (Fig5G). Larger clones 420 
of SOX2 derivatives were observed at P63 in Sox2CreERT2/+;R26rtTA/mTmG;Col1a1tetO-421 
Yap/+ animals compared to controls, and these still contained SOX2+ cells (Fig5H). 422 
Following withdrawal, we were able to detect GFP+ derivatives of SOX2+ cells, 423 
which had differentiated into the three lineages (PIT1, SF1 and ACTH, marking 424 
corticotrophs of the TPIT lineage) (Fig5I). Taken together, these findings confirm that 425 
sustained expression of YAP is sufficient to maintain the SOX2+ state and promote 426 
activation of normal SOX2+ pituitary stem cells in vivo, driving expansion of this 427 
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population. 428 
429 
430 
DISCUSSION 431 
 432 
Here we establish that regulation of LATS/YAP/TAZ signaling is essential during 433 
anterior pituitary development and can influence the activity of the stem/progenitor 434 
cell pool. LATS kinases, mediated by YAP and TAZ, are responsible for controlling 435 
organ growth, promoting an undifferentiated state and repressing lineage 436 
commitment. Loss of both Lats1 and Lats2, encoding potent tumour suppressors, 437 
leads to dramatic tissue overgrowth during gestation, revealing a function for these 438 
enzymes in restricting growth during pituitary development. The involvement of 439 
YAP/TAZ and dysfunction of the kinase cascade is emerging in multiple paediatric 440 
cancers, which are often developmental disorders37.  441 
 442 
Loss of LATS1 heterozygosity has been reported in a range of human tumours38, 39, 40, 443 
41 leading to an increase in YAP/TAZ protein levels. Previous global deletion of Lats1 444 
in mice resulted in a variety of soft tissue sarcomas and stromal cell tumours42. The 445 
anterior lobe of these animals appeared hyperplastic with poor endocrine cell 446 
differentiation leading to combined hormone deficiencies, but the presence of tumours 447 
was not noted. We report that loss of Lats1 alone is sufficient to drive anterior and 448 
intermediate lobe tumour formation. This phenotype is accelerated following 449 
additional deletion of one copy of Lats2. Phenotypically identical tumour lesions were 450 
generated when the genetic deletions were carried out embryonically in RP, or at 451 
postnatal stages. Interestingly, tissue-specific loss of Stk3 and Stk4, which regulate 452 
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LATS activation in other tissues43, did not lead to any pituitary defects despite 453 
reduction in STK3/4 levels. These data suggest that perhaps the residual activity of 454 
STK3/4 is sufficient for LATS1/2 activation. Alternatively, regulation of LATS1/2 by 455 
kinases other than STK3/4 is possible in the pituitary, meaning deletion of Stk3/4 456 
alone is insufficient to result in significant LATS function impairment. Similar 457 
situations have been reported in other organs where LATS are functioning43. The 458 
resulting non-secreting tumours in our mouse models are composed predominantly of 459 
SOX2+ stem cells and display signs of squamous differentiation. Rare cases of 460 
squamous cell carcinoma have been reported as primary pituitary tumours44, but more 461 
frequently, arising within cysts that are normally non-neoplastic epithelial 462 
malformations45, 46. In the embryonic YAP-TetO model, where constitutive active 463 
YAP (S127A) was expressed during pituitary development, cysts phenocopying 464 
Rathke’s cleft cyst, develop by postnatal stages. Target elevation is not as high in 465 
YAP-TetO pituitaries, as following the deletion of LATS1/2, indicating that signaling 466 
levels are likely to be critical for progression between these phenotypes. 467 
Although human pituitary carcinomas are only diagnosed as such after metastasis, the 468 
tumours generated in our LATS1/2 mouse models fit their histopathological profile. 469 
Genetic lineage tracing identified SOX2+ cells as the cell of origin of the tumours; 470 
this observation could have ramifications regarding involvement of the 471 
LATS/YAP/TAZ pathway in the establishment or progression of human pituitary 472 
tumours composed of uncommitted cells. In cancer stem cells of osteosarcoma and 473 
glioblastoma, SOX2 antagonises upstream Hippo activators, leading to enhanced 474 
YAP function47. We recently reported enhanced expression of YAP/TAZ in a range of 475 
non-functioning human pituitary tumours, compared to functioning adenomas, and 476 
that Lats1 knock-down in GH3 pituitary mammosomatotropinoma cells results in 477 
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repression of the Gh and Prl promoters28. Therefore, YAP/TAZ, perhaps in a positive 478 
feedback loop with SOX2, are likely to function both to promote the maintenance of 479 
an active pituitary stem cell state as well as to inhibit differentiation.  480 
 481 
By dissecting the downstream requirement for YAP in pituitary regulation by the 482 
LATS/YAP/TAZ axis, we found that expression of constitutively active YAP 483 
(S127A) is sufficient to push SOX2+ pituitary stem cells into an activated state, 484 
leading to expansion of the stem cell cohort (see Model, Fig6). YAP has previously 485 
been indicated to promote the stem cell state in other tissues, e.g. pancreas, neurons, 486 
mammary glands48.  However, this does not fully recapitulate the LATS deletion 487 
phenotypes, as it did not lead to the formation of tumours during the time course of 488 
YAP activation (12 weeks). Interestingly, since the levels of target activation are 489 
significantly greater in Lats1/2 deletions that in YAP-TetO activation, initiation of 490 
tumourigenesis may be associated with levels of signalling rising above a threshold. 491 
However, the temporal control of expressing the mutation is critical, as seen in other 492 
tumour models49. Instead, the findings identify an isolated role for YAP in promoting 493 
the expansion of the SOX2+ stem cell pool and restoring their proliferative potential 494 
to levels akin to the most active state during postnatal pituitary growth. Activity of 495 
YAP/TAZ is reduced in dense tissues, resulting in a decrease in stemness. One 496 
mechanism through which this is achieved is by crosstalk with other signaling 497 
pathways regulating stem cell fate50, 51. For example, a decrease in YAP/TAZ activity 498 
removes inhibition on Notch signalling, resulting in higher levels of differentiation 499 
and a drop in stem cell potential52. In the pituitary, Notch plays a role in the 500 
maintenance of the SOX2 stem cell compartment and is involved in regulating 501 
differentiation53, 54, 55, 56. The downstream mechanisms of YAP action on SOX2+ 502 
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pituitary stem cells, as well as the likely crosstalk with other signalling pathways 503 
remain to be explored. 504 
 505 
In summary, our findings highlight roles for LATS/YAP/TAZ in the regulation of 506 
pituitary stem cells, where fine-tuning of their expression can make the difference 507 
between physiological stem cell re-activation and tumourigenesis, of relevance to 508 
other organs. We reveal this axis is involved in the control of cell fate commitment, 509 
regulation of regenerative potential and promotion of tumourigenesis. These findings 510 
can aid in the design of treatments against pituitary tumours and in regenerative 511 
medicine approaches targeting the regulation of endogenous stem cells.  512 
 513 
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 528 
MATERIALS & METHODS 529 
Key Resources Table 530 
Reagent type 
(species) or 
resource 
Designation Source or 
reference 
Identifiers Additional 
Information 
Genetic reagent 
(M. musculus) 
Hesx1Cre/+ PMID: 
17360769 
RRID:MGI:5314529 
 
 
Genetic reagent 
(M. musculus) 
Sox2CreERT2/+ PMID: 
24094324 
MGI:5512893 
 
 
Genetic reagent 
(M. musculus) 
Lats1fl/fl Jackson 
Laboratory 
Stock #: 024941, 
RRID: MGI:5568576 
 
Genetic reagent 
(M. musculus) 
Lats2fl/fl Jackson 
Laboratory 
Stock #: 025428, 
RRID: MGI:5568577 
 
Genetic reagent 
(M. musculus) 
Stk4fl/fl;Stk3fl/fl Jackson 
Laboratory 
Stock  #: 017635, 
RRID: MGI:5301573 
PMID: 
20080689 
Genetic reagent 
(M. musculus) 
R26rtTA/+ Jackson 
Laboratory 
Stock: #: 016999 
RRID: MGI:5292520 
 
PMID: 
15941831 
 
Genetic reagent 
(M. musculus) 
Col1a1tetO-Yap/+ PMID: 
22363786 
MGI:5430522 
 
 
Genetic reagent 
(M. musculus) 
R26mTmG/+ Jackson 
Laboratory 
Stock #: 007576 
RRID:MGI:3722405 
 
PMID: 
17868096 
Genetic reagent Taz-/- Jackson Stock #: 011120, PMID: 
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(M. musculus) Laboratory RRID: MGI:4420900 17636028 
Genetic reagent 
(M. musculus) 
Yapfl/fl PMID: 
21376238 
MGI:5316446 
 
 
Antibody Rabbit 
polyclonal anti-
TAZ 
Atlas 
Antibodies 
Cat# HPA007415 
RRID:AB_1080602 
IF: 1:1000 
 
Antibody Rabbit 
polyclonal anti-
YAP 
Cell Signaling 
Technology  
Cat# 4912S 
RRID:AB_2218911 
IF: 1:1000 
 
Antibody Rabbit 
polyclonal anti-
pYAP 
Cell Signaling 
Technology 
Cat# 4911S 
RRID:AB_2218913 
IF: 1:1000 
 
Antibody Rabbit 
polyclonal anti-
SOX2 
Abcam  Cat# ab97959 
RRID:AB_2341193 
IF: 1:2000 
Antibody Rat monoclonal 
anti-EMCN 
(V.7C7.1) 
Abcam  Cat# ab106100 
RRID:AB_10859306 
IF: 1:1000 
Antibody Chicken 
polyclonal anti-
GFP 
Abcam  Cat# ab13970 
RRID:AB_300798 
IF: 1:300 
Antibody Goat polyclonal 
anti-SOX2 
Immune 
Systems 
Limited  
Cat# GT15098 
RRID:AB_2732043 
IF: 1:250 
Antibody Rabbit Abcam  Cat# ab16667 IF: 1:300 
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monoclonal 
anti-Ki-67 
RRID:AB_302459 
Antibody Rabbit 
polyclonal anti-
ARL13B 
Proteintech 
Group 
Cat# 17711-1-AP, 
RRID:AB_2060867 
IF: 1:100 
Antibody Mouse 
monoclonal 
anti-Acetylated-
DTUB 
Sigma-Aldrich Cat# MABT868 IF: 1:200 
Antibody Rabbit 
monoclonal 
anti-SOX9 
Abcam  Cat# ab185230 
RRID:AB_2715497 
IF: 1:300 
Antibody Rabbit 
monoclonal 
anti-Active YAP  
EPR19812 
Abcam  Cat# ab205270 IF: 1:300 
Antibody Rabbit 
polyclonal anti-
PIT1  
Prof. S. 
Rhodes 
(Indiana 
University 
 IF: 1:1000 
Antibody Rabbit 
polyclonal anti-
TPIT 
Prof. J. Drouin 
(Montreal 
IRCM) 
 IF: 1:1000 
Antibody Mouse 
monoclonal 
Life 
Technologies  
Cat# N1665 
RRID:AB_2532209 
IF: 1:200 
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anti-SF1 (Thermo 
Fisher 
Scientific) 
Antibody Rabbit 
polyclonal anti-
gamma H2A.X  
(phospho S139)  
Abcam 
 
Cat# ab2893 
RRID:AB_303388 
IF: 1:1000 
Antibody Rabbit 
polyclonal anti-
STK3/4 
Bethyl 
Laboratories 
Cat# A300-466A 
RRID:AB_2148394 
WB: 
1:5000 
Antibody Mouse 
monoclonal 
anti-Cyclophilin 
B 
(Clone# 
549205)  
R&D Systems Cat# MAB5410 
RRID:AB_2169416 
 
WB: 
1:1000 
Antibody Rabbit 
monoclonal 
anti-Vimentin 
(D21H3) 
Cell Signaling 
Technology 
Cat# 5741 
RRID:AB_10695459 
 
IF: 1:300 
Antibody Biotinylated 
Goat polyclonal 
anti-rabbit  
Abcam  Cat# ab6720 
RRID:AB_954902 
IF: 1:350 
Antibody Goat polyclonal 
anti-chicken 
Life 
Technologies 
Cat# A11039 
RRID:AB_2534096 
IF: 1:300 
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Alexa Fluor 488  (Thermo 
Fisher 
Scientific) 
Antibody Goat polyclonal 
anti-rat Alexa 
Fluor 555  
Life 
Technologies  
(Thermo 
Fisher 
Scientific) 
Cat# A21434 
RRID:AB_2535855 
IF: 1:300 
Antibody Biotinylated 
Goat polyclonal 
anti-mouse 
Abcam  Cat# ab6788 
RRID:AB_954885 
IF: 1:350 
Antibody Donkey 
polyclonal anti-
goat Alexa Fluor 
488  
Abcam  Cat# ab150133 IF: 1:300 
Antibody Streptavidin 
Alexa Fluor 555 
Life 
Technologies  
Cat# S21381 
RRID:AB_2307336 
IF: 1:500 
Antibody Goat HRP-
linked anti-
rabbit 
Cell Signaling 
Technology 
Cat# 7074 
RRID:AB_2099233 
WB: 
1:2000 
Antibody Goat HRP-
linked anti-
mouse 
Cell Signaling 
Technology 
Cat# 7076 
RRID:AB_330924 
WB: 
1:2000 
Antibody Mouse 
monoclonal 
Dako Cat# M351529 IHC: 1:100 
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anti-AE1/AE3 
Antibody Mouse 
monoclonal 
anti-
Chromogranin 
Dako Cat# M086901 IHC: 1:400 
Antibody Mouse 
monoclonal 
anti-NCAM 
Novocastra Cat# NCL-L-CD56-
504 
IHC 1:15 
Antibody Mouse 
monoclonal 
anti-NSE 
Dako Cat# M087329 IHC 1:1000 
Antibody Mouse 
monoclonal 
anti-p63 
A. Menarini 
Diagnostics 
Cat# MP163 IHC 1:100 
Antibody Mouse 
monoclonal 
anti-
Synaptophysin 
Dako Cat# M731529 
RRID:AB_2687942 
IHC 1:2 
Commercial 
assay or kit 
TSA kit Perkin Elmer Cat# NEL753001KT  
Commercial 
assay or kit 
TSA Blocking 
Reagent 
Perkin Elmer Cat# FP1020  
Commercial 
assay or kit 
ABC kit Vector 
Laboratories 
Cat# Vector PK-6100 
RRID:AB_2336819 
 
Commercial BCA assay Thermo Fisher Cat# 23227  
 28 
assay or kit 
Commercial 
assay or kit 
UltraView 
Universal DAB 
Detection Kit 
Ventana 
Medical 
Systems 
Cat# 760-500  
Commercial 
assay or kit 
VectaFluor 
Excel R.T.U. 
Antibody Kit, 
DyLight 488 
Anti-Mouse 
Vector 
Laboratories 
Cat# DK-2488 
RRID:AB_2336775 
 
Chemical 
compound, drug 
Doxycycline 
hyclate 
Alfa Aesar Cat# J60579 2mg/ml 
Chemical 
compound, drug 
Sucrose Sigma-Aldrich Cat# S0389 10mg/ml 
Chemical 
compound, drug 
Tamoxifen Sigma-Aldrich Cat# T5648 0.15mg/g 
Chemical 
compound, drug 
Hoechst 33342 Life 
Technologies 
Cat# H3570 1:10000 
Chemical 
compound, drug 
Laemmli buffer Bio-Rad Cat# 1704156  
Chemical 
compound, drug 
Clarity Western 
ECL Substrate 
Bio-Rad Cat# 170-5060  
Chemical 
compound, drug 
Alcian Blue Alfa Aeser Cat# J60122 1% 
Chemical 
compound, drug 
Acetic acid VWR Cat# 20103 3% 
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Chemical 
compound, drug 
Periodic acid VWR Cat# 29460 1% 
Chemical 
compound, drug 
Schiff’s reagent Thermo Fisher 
Scientific 
Cat# 88017  
Software, 
algorithm 
GraphPad Prism GraphPad 
Software 
(www.graphpa
d.com) 
RRID:SCR_015807 
 
 
Software, 
algorithm 
Fiji Schindelin et 
al., 2012 
(Fiji.sc) 
RRID:SCR_002285 
 
 
Software, 
algorithm 
ImageLab BioRad   
Other Probe: Ctgf ACDBio Cat# 314541  
Other Probe: Cyr61 ACDBio Cat# 429001  
Other Probe: Lats2 ACDBio Cat# 420271  
Other Probe: Nr5a1 ACDBio Cat# 445731  
Other Probe: Tbx19 ACDBio Cat# 484741  
Other Probe: Pou1f1 ACDBio Cat# 486441  
 531 
 532 
 533 
Animals 534 
Animal husbandry was carried out under compliance of the Animals (Scientific 535 
Procedures) Act 1986, Home Office license and KCL ethical review approval. 536 
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The Hesx1Cre/+ 57, Sox2CreERT2/+ 1, Yapfl/fl 25, Taz-/- 30(JAX:011120), R26mTmG/+ 537 
58(JAX:007576), ROSA26rtTA/+ 59 (JAX:016999), Col1a1tetO-Yap/+ 60(MGI:5430522), 538 
Stk3fl/fl;Stk4fl/fl 61(JAX:017635), and Lats1fl/fl  51(JAX:024941) and Lats2fl/fl  539 
51(JAX:025428) have been previously described. 540 
Tamoxifen (Sigma, T5648) was administered to experimental mice by intraperitoneal 541 
injection at a single dose of 0.15mg/g body weight, or two equal doses on sequential 542 
days, depending on the experiment. Mice for growth studies were weighed every 543 
week. For embryonic studies, timed matings were set up where noon of the day of 544 
vaginal plug was designated as 0.5dpc.  545 
For YAP-TetO experiments, crosses between Hesx1Cre/+;R26+/+;Col1a1+/+ and 546 
Hesx1+/+;R26rtTA/rtTA;Col1a1tetO-Yap/ tetO-Yap animals were set up to generate 547 
Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ offspring (hereby YAP-TetO) and control 548 
littermates, or crosses between Sox2CreERT2/+;R26mTmG/mTmG;Col1a1+/+ and Sox2+/+; 549 
R26rtTA/rtTA;Col1a1tetO-Yap/ tetO-Yap animals were set up to generate 550 
Sox2CreERT2/+;R26rtTA/mTmG;Col1a1tetO-Yap/+ offspring. Whilst treated with the 551 
tetracycline analogue doxycycline, YAP-TetO expressed rtTA from the ROSA26 552 
locus in Cre-derived cells, enabling YAP S127A expression from the Col1a1 locus. 553 
For embryonic studies between 5.5dpc and 15.5dpc (scheme, Fig1A), doxycycline 554 
(Alfa Aesar, J60579) was administered to pregnant dams in the drinking water at 555 
2mg/ml, supplemented with 10% sucrose. For postnatal analyses animals were treated 556 
with doxycycline or vehicle (DMSO) as described, from the ages specified for 557 
individual experiments on the Hesx1Cre/+ driver, or directly following tamoxifen 558 
administration for animals on the Sox2CreERT2/+ driver. Both male and female mice and 559 
embryos where included in the studies. 560 
 561 
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Tissue preparation 562 
Embryos and adult pituitaries were fixed in 10% neutral buffered formalin (Sigma) 563 
overnight at room temperature. The next day, tissue was washed then dehydrated 564 
through graded ethanol series and paraffin-embedded. Embryos up to 13.5dpc were 565 
sectioned sagittal and all older embryo and postnatal samples were sectioned frontal, 566 
at a thickness of 7µm for immunofluorescence staining, or 4µm for RNAscope 567 
mRNA in situ hybridisation.  568 
 569 
RNAscope mRNA in situ hybridisation 570 
Sections were selected for the appropriate axial level, to include Rathke’s pouch or 571 
pituitary, as described previously 27. The RNAscope 2.5 HD Reagent Kit-RED assay 572 
(Advanced Cell Diagnostics) was used with specific probes: Ctgf, Cyr61, Lats2 (all 573 
ACDBio). 574 
 575 
H&E staining 576 
Sections were dewaxed in histoclear and rehydrated through graded ethanol series 577 
from 100% to 25% ethanol, then washed in distilled H2O. Sections were stained with 578 
Haematoxylin QS (Vector #H3404) for 1 minute, and then washed in water. Slides 579 
were then stained in eosin in 70% ethanol for 2 minutes and washed in water. Slides 580 
were dried and coverslips were mounted with VectaMount permanent mounting 581 
medium (Vector Laboratories H5000). 582 
 583 
Immunofluorescence and immunohistochemistry 584 
Slides were deparaffinised in histoclear and rehydrated through a descending graded 585 
ethanol series. Antigen retrieval was performed in citrate retrieval buffer pH6.0, using 586 
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a Decloaking Chamber NXGEN (Menarini Diagnostics) at 110°C for 3mins. 587 
Tyramide Signal Amplification (TSA) was used for staining using antibodies against 588 
YAP (1:1000, Cell Signaling #4912S), pYAP (1:1000, Cell Signaling #4911S), TAZ 589 
(1:1000, Atlas Antibodies #HPA007415) and SOX2 (1:2000, Abcam ab97959) with 590 
EMCN (1:1000, Abcam ab106100) staining as follows: sections were blocked in TNB 591 
(0.1M Tris-HCl, pH7.5, 0.15M NaCl, 0.5% Blocking Reagent (Perkin Elmer 592 
FP1020)) for 1 hour at room temperature, followed by incubation with primary 593 
antibody at 4C overnight, made up in TNB. Slides were washed three times in TNT 594 
(0.1MTris-HCl pH7.5, 0.15M NaCl, 0.05% Tween-20) then incubated with secondary 595 
antibodies (biotinylated anti-rabbit (1:350 Abcam ab6720) and anti-Rat Alexa Fluor 596 
555 (1:300, Life Technologies A21434) for 1 hour at room temperature and Hoechst 597 
(1:10000, Life Technologies H3570). Slides were washed again then incubated in 598 
ABC reagent (ABC kit, Vector Laboratories PK-6100) for 30 mins, followed by 599 
incubation with TSA conjugated fluorophore (Perkin Elmer NEL753001KT) for ten 600 
minutes. Slides were washed and mounted with VectaMount (Vector Laboratories 601 
H1000). 602 
For regular immunofluorescence sections were blocked in blocking buffer (0.15% 603 
glycine, 2mg/ml BSA, 0.1% Triton-X in PBS), with 10% sheep serum (donkey serum 604 
for goat SOX2 antibody) for 1 hour at room temperature, followed by incubation with 605 
primary antibody at 4C overnight, made up in blocking buffer with 1% serum. 606 
Primary antibodies used were against SOX2 (1:250, Immune Systems Ltd GT15098), 607 
active YAP (1:300, Abcam ab205270), GFP (1:300, Abcam ab13970), Ki-67 (1:300, 608 
Abcam ab16667), SOX9 (1:300, Abcam ab185230), PIT1 (1:1000, Gift from S. 609 
Rhodes, Indiana University), TPIT (1:1000, Gift from J. Drouin, Montreal), SF1 610 
(1:200, Life Technologies N1665), Gamma H2A.X (1:1000, Abcam ab2893), 611 
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Vimentin (1:300, Cell Signaling #5741), Caspase (1:300, Cell Signaling #9661S). 612 
Slides were washed in PBST then incubated with secondary antibodies for 1 hour at 613 
room temperature. Appropriate secondary antibodies were incubated in blocking 614 
buffer for 1 hr at room temperature (biotinylated anti-rabbit (1:350, Abcam ab6720), 615 
biotinylated anti-mouse (1:350, Abcam ab6788), anti-chicken 488 (1:300, Life 616 
Technologies A11039), anti-goat 488 (1:300, Abcam ab150133). Slides were washed 617 
again using PBST and incubated with fluorophore-conjugated Streptavidin (1:500, 618 
Life Technologies S21381 or S11223) for 1 hour at room temperature, together with 619 
Hoechst (1:10000, Life Technologies H3570). Slides were washed in PBST and 620 
mounted with VectaMount (Vector Laboratories, H1000). 621 
 622 
Immunohistochemistry for the remaining antigens were undertaken on a Ventana 623 
Benchmark Autostainer (Ventana Medical Systems) using the following primary 624 
antibodies and antigen retrieval: AE1/AE3 (1:100, Dako M351529), CC1 (36 625 
minutes, Ventana Medical Systems 950-124); Chromogranin (1:400, Dako 626 
M086901), CC1 (36 minutes, Ventana Medical Systems 950-124); NCAM (1:15, 627 
Novocastra NCL-L-CD56-504), CC1 (64 minutes, Ventana Medical Systems 950-628 
124); NSE (1:1000, Dako M087329), CC1 (36 minutes, Ventana Medical Systems 629 
950-124); p63 (1:100, A. Menarini Diagnostics), CC1 (64 minutes, Ventana Medical 630 
Systems 950-124) and Synaptophysin (1:2, Dako M731529), CC2 (92 minutes, 631 
Ventana Medical Systems 950-124). Targets were detected and viewed using the 632 
ultraView Universal DAB Detection Kit (Ventana Medical Systems, 760-500) 633 
according to manufacturer’s instructions. 634 
 635 
Alcian Blue with Periodic Acid-Schiff staining (AB/PAS) 636 
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Following deparaffinisation and rehydration, sections were taken through distilled 637 
water then placed in Alcian Blue solution (1% Alcian Blue (Alfa Aeser J60122) in 638 
3% acetic acid (VWR International 20103)) for 20 minutes. Sections were then placed 639 
in 1% periodic acid (VWR 29460) for 10 minutes, washed in distilled water and 640 
transferred to Schiff’s reagent (Thermo Fisher Scientific 88017) for 10 minutes, 641 
followed by washing in distilled water for 5 minutes. Sections were then routinely 642 
dried, cleared and mounted. 643 
 644 
Western blotting 645 
Dissected anterior pituitaries were flash frozen in liquid nitrogen and stored at -80°C. 646 
Frozen pituitaries were each lysed in 30µl of lysis buffer (5mM Tris, 150mM NaCl, 647 
1% protease and phosphatase inhibitor (Abcam ab201119), 5PM EDTA, 0.1% Triton-648 
X, pH7.6) and sonicated at 40% power, twice for ten cycles of: two seconds on/two 649 
seconds off, using a Vibra-Cell Processor (Sonics). Protein concentration was 650 
determined using the Pierce BCA protein assay kit (Thermo #23227) and all samples 651 
were diluted to 4mg/ml in Laemmli buffer (Biorad #161-0747). Proteins were 652 
denatured at 95°C for 5 minutes. Samples were run on a 10% Mini-PROTEAN TGX 653 
polyacrylamide gel (BioRad #4561033), then transferred using Trans-Blot Turbo 654 
transfer machine (BioRad) onto polyvinylidene difluoride membranes (BioRad 655 
#1704156). Membranes were blocked with 5% non-fat dairy milk (NFDM) in TBST 656 
(20mM Tris, 150mM NaCl, 0.1% Tween-20, pH7.6), cut, then incubated with 657 
primary antibodies overnight at 4°C as follows: anti-STK3/STK4 (1:5000, Bethyl 658 
Laboratories #A300-466A) or Cyclophilin B (1:1000, R&D Systems #MAB5410) in 659 
5%NFDM. The next day, membranes were washed in TBST, incubated with 660 
secondary antibodies HRP-conjugated anti-Rabbit (1:2000, Cell Signaling #7074) or 661 
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HRP-conjugated anti-Mouse (1:2000, Cell Signaling #7076) in 5% NFDM for 1hr at 662 
room temperature. After washing in TBST, membranes were treated with Clarity 663 
Western ECL substrate (Biorad #170-5060) and bands visualised using the ChemiDoc 664 
Touch Imaging System (BioRad). Protein abundance was analysed using ImageLabs 665 
(BioRad). 666 
 667 
Imaging 668 
Wholemount images were taken with a MZ10 F Stereomicroscope (Leica 669 
Microsystems), using a DFC3000 G camera (Leica Microsystems). For bright field 670 
images, stained slides were scanned with Nanozoomer-XR Digital slide scanner 671 
(Hamamatsu) and images processed using Nanozoomer Digital Pathology View. 672 
Fluorescent staining was imaged with a TCS SP5 confocal microscope (Leica 673 
Microsystems) and images processed using Fiji 62.  674 
 675 
Quantifications and Statistics 676 
Cell counts were performed manually using Fiji cell counter plug-in; 5-10 fields were 677 
counted per sample, totalling over 1500 nuclei, across 3-7 pituitaries. Statistical 678 
analyses and graphs were generated in GraphPad Prism (GraphPad Software) and the 679 
following tests were performed to determine significance: Student’s t-tests between 680 
controls and mutants for Figures 1D, 2D, S1bD, S1bE (n=3 of each genotype), S4 681 
(n=4 of each genotype) and 5C (n=4-5 of each genotype); unpaired t-test for Figures 682 
S2bA (n=3 per genotype) and S2bF (n=6 sections across two samples per genotype); 683 
two-tailed t-test for Figure 3C (n=3 controls, 7 mutants); two-way ANOVA with 684 
Sidak’s multiple-comparison test for Figures 5F (n=4-5 of each genotype). For 685 
quantification of target expression by RNAscope mRNA in situ hybridisation (Figure 686 
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S5), the area of positive staining (red fluorescence) from 4Pm sections was 687 
determined from images using thresholding in Fiji, and quantified as a percentage of 688 
total pituitary area in the same image. For statistical testing, one-way ANOVAs with 689 
Tukey’s multiple comparisons were performed (n=4 mutants per genotype). Error 690 
bars in graphs show ± standard error of the mean, unless otherwise indicated. 691 
Quantification of STK3/4 by western blot was carried out on 2 control 692 
(Stk3fl/fl;Stk4fl/fl) and 3 mutant (Hesx1Cre/+;Stk3fl/fl; Stk4fl/fl) samples. A Student’s t-test 693 
was carried out on normalised band intensities. Chi-squared tests were used to 694 
determine significant deviations of observed from expected genotypes presented as 695 
tables in Supplementary Files 1 and 2. 696 
 697 
 698 
FIGURE LEGENDS 699 
Figure 1 Regulation of YAP is required for normal morphogenesis and lineage 700 
commitment during pituitary development. 701 
A. Schematic outlining the time course of doxycycline (DOX) treatment administered 702 
to pregnant dams from Hesx1Cre/+ x R26rtTA/rtTA;Col1a1tetO-Yap/tetO-Yap crosses for the 703 
embryonic induction of YAP(S127A) expression in Hesx1Cre/+;R26rtTA/+;Col1a1tetO-704 
Yap/+ (YAP-TetO) mutant embryos as well as controls that do not express 705 
YAP(S127A) (Hesx1+/+;R26rtTA/+;Col1a1tetO-Yap/+ controls shown here). B. 706 
Immunofluorescence staining against YAP and TAZ on frontal pituitary sections at 707 
15.5dpc confirms accumulation of YAP protein in YAP-TetO compared to control 708 
sections, but no increase in TAZ levels. RNAscope mRNA in situ hybridisation 709 
against the YAP/TAZ target Cyr61 confirms an increase in transcripts in the anterior 710 
pituitary as well as the hypothalamus where the Cre is also active (arrows). C. 711 
Haematoxylin and eosin staining of frontal pituitary sections from 15.5dpc control 712 
and YAP-TetO embryos showing pituitary dysmorphology in mutants. 713 
Immunofluorescence staining for LHX3 to mark anterior pituitary tissue and SOX2 to 714 
mark pituitary progenitors shows the persistence of SOX2 protein in lateral regions of 715 
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the gland in YAP-TetO mutants (arrowheads) when they have lost SOX2 expression 716 
in controls (arrows) (magnified boxed region in SOX2, corresponding to dashed box 717 
in LHX3). D. Immunofluorescence staining for lineage-committed progenitor markers 718 
PIT1, TPIT and SF1 reveals very few cells expressing commitment markers in YAP-719 
TetO compared to control. Graph showing quantification of committed cells of the 720 
three anterior pituitary endocrine lineages, positive for PIT1, TPIT and SF1, as a 721 
percentage of total nuclei of Hesx1+/+;R26rtTA/+;Col1a1tetO-Yap/+ control and 722 
Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ (YAP-TetO) mutant pituitaries at 15.5dpc 723 
(Student’s t-test; PIT1: P<0.0001 (****), TPIT: P=0.0012 (**), SF1: P=0.0021 (**)). 724 
Scale bars 100µm, 50µm in magnified boxed regions in C. See also figure 725 
supplements 1 and 2. 726 
 727 
Figure 2 Pituitary-specific deletion of Lats1 and Lats2 during development leads 728 
to pituitary overgrowth and defects in lineage commitment. 729 
A. Haematoxylin and eosin staining on sagittal sections from 730 
Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl  (mutant) and Hesx1+/+;Lats1fl/fl;Lats2fl/fl  (control) 731 
embryos at 13.5dpc reveals anterior pituitary dysmorphology and overgrowth in 732 
mutants (dashed outline). Immunofluorescence staining for TAZ, YAP and pYAP 733 
reveals accumulation of TAZ and YAP in overgrown mutant tissue (arrowheads, 734 
normal epithelial expression indicated by arrows in control) and lack of staining for 735 
pYAP (S127). Immunofluorescence for SOX2 shows the presence of SOX2+ 736 
progenitors throughout the abnormal tissue in mutants. B. Immunofluorescence 737 
staining for late progenitor marker SOX9 shows localisation in few cells of the 738 
pituitary of mutants at 13.5dpc. Immunofluorescence staining for Ki-67 indicates 739 
cycling cells throughout the mutant pituitary. C. Immunofluorescence staining for 740 
SOX2 and Endomucin (EMCN) on frontal pituitary sections at 15.5dpc shows 741 
expansion of the SOX2+ progenitor compartment compared to controls and a 742 
reduction in vasculature marked by Endomucin. Immunofluorescence for non-743 
phosphorylated (Active) YAP shows strong expression throughout the mutant gland 744 
compared to the control. Areas of necrosis in mutant tissue indicated by asterisks. 745 
Ventral overgrowth extending into the oral cavity between the condensing sphenoid 746 
bone indicated by arrows. D. Immunofluorescence staining for lineage-committed 747 
progenitor markers PIT1, TPIT and SF1 reveals only sporadic cells expressing 748 
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commitment markers in Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl  mutants compared to controls. 749 
Boxes showing magnified regions. Dashed lines demarcate anterior pituitary tissue. 750 
Graph showing quantification of committed cells of the three anterior pituitary 751 
endocrine lineages, positive for PIT1, TPIT and SF1, as a percentage of total nuclei of 752 
Hesx1+/+;Lats1fl/fl;Lats2fl/fl  control and Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl  mutant pituitaries 753 
at 15.5dpc (Student’s t-test; PIT1: P<0.0001 (****), TPIT: P=0.007 (**), SF1: 754 
P>0.05). Scale bars 100µm. See also figure supplement 2. 755 
 756 
Figure 3 Pituitary specific loss of Lats1 leads to tumour formation. 757 
A. Haematoxylin and eosin staining of frontal sections from 758 
Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ (mutant) and control pituitaries at P56 demonstrates 759 
overgrown tumourigenic regions in mutants. These show focal necrosis, cysts and a 760 
squamous morphology (magnified regions) not seen in controls. Asterisk indicates 761 
necrosis. B. Immunofluorescence staining for TAZ, YAP and pYAP(S127) show 762 
accumulation of TAZ and YAP but not pYAP in the mutant but not in the control. 763 
RNAscope mRNA in situ hybridisation against YAP/TAZ targets Ctgf and Cyr61 764 
reveals an increase in transcripts on mutant tissue compared to control. C. Graph of 765 
the proliferation index in control and mutant samples at P56 shows a significant 766 
increase in cycling cells in the Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ mutant pituitaries 767 
compared to controls (control percentage Ki-67: 2.967±1.2 SEM, n=3; mutant: 768 
15.46±2.74 n=7. P=0.0217 (*), two-tailed t-test). Images show representative 769 
examples of Ki-67 immunofluorescence staining. D. Immunofluorescence staining for 770 
lineage-committed progenitor markers PIT1, TPIT and SF1 shows the near absence of 771 
committed cells in tumours.  E. Immunofluorescence staining for pituitary stem cell 772 
markers SOX2 and SOX9 reveal that tumour lesions have abundant positive cells 773 
compared to the control, whilst Endomucin (EMCN) staining shows poor 774 
vascularisation. F. The marginal zone epithelium of Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ 775 
mutant pituitaries develops invaginations as seen by haematoxylin and eosin staining. 776 
Immunofluorescence staining against SOX2 shows the maintenance of a single-777 
layered epithelium. Scale bars 100 µm. Boxes indicate magnified regions. See also 778 
figure supplement 1. 779 
 780 
Figure 4 SOX2+ pituitary stem cells are the cell-of-origin of tumours generated 781 
in the absence of Lats1. 782 
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A. Schematic outlining the experimental time line of inductions in 783 
Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ (mutant) and Sox2+/+;Lats1fl/fl;Lats2fl/+ (control) 784 
animals. Representative images of haematoxylin and eosin staining of frontal sections 785 
of control and mutant pituitaries at P35, revealing a hyperplastic anterior pituitary in 786 
the mutant with areas of necrosis (asterisks). B. Immunofluorescence staining reveals 787 
tumourigenic lesions in Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ that display increased levels of 788 
TAZ and YAP staining compared to the control. C. RNAscope mRNA in situ 789 
hybridisation against Ctgf and Cyr61 shows elevated transcripts in tumourigenic 790 
lesions. Insets (i) and (ii) show invaginations in the epithelium of the mutant. D. 791 
Immunofluorescence staining for lineage-committed progenitor markers PIT1, TPIT 792 
and SF1 showing a reduction in staining in tumourigenic lesions compared to control 793 
pituitaries. E. Lineage tracing of SOX2+ cells in 794 
Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+R26mTmG/+ reveals that tumour regions accumulating 795 
YAP as seen by immunofluorescence, are composed of GFP+ cells at P35. Scale bars 796 
500µm in A; 100µm in B, D, E; 250µm in C. See also figure supplement 1. 797 
 798 
Figure 5 Postnatal expression of constitutively active YAP increases leads to an 799 
activation of SOX2+ pituitary stem cells. 800 
A. Schematic outlining the time course of doxycycline (DOX) treatment administered 801 
to Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ (YAP-TetO) and Hesx1+/+;R26rtTA/+;Col1a1tetO-802 
Yap/+ controls to drive expression of YAP-S127A in mutant pituitaries. B. At P42 (3 803 
weeks of treatment), immunofluorescence staining on frontal anterior pituitary 804 
sections detects strong total YAP expression in YAP-TetO mutants compared to the 805 
control and no increase in pYAP(S127). Immunofluorescence for SOX2 and SOX9 806 
reveals an expanded population of stem cells in YAP-TetO compared to control 807 
(quantification in F). C. Graph showing the percentage of double Ki-67+SOX2+ cells 808 
as a proportion of the total SOX2+ (P=0.027 (*)) or Ki-67+ (P=0.006 (**)) 809 
populations at P42 (n=3 pituitaries per genotype). There is an increase in the numbers 810 
of cycling SOX2 cells in YAP-TetO mutant compared to controls. The image shows a 811 
representative example of double immunofluorescence staining against Ki-67 and 812 
SOX2 in a control and YAP-TetO section. D. Schematic outlining the time course of 813 
doxycycline (DOX) treatment administered to Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ 814 
(YAP-TetO) and Hesx1+/+;R26rtTA/+;Col1a1tetO-Yap/+ controls to drive expression of 815 
YAP-S127A in mutant pituitaries for three weeks, followed by a three-week recovery 816 
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period in the absence of DOX. E. Immunofluorescence staining against YAP, SOX2 817 
and SOX9 on control and YAP-TetO pituitaries treated as in D, shows comparable 818 
expression of YAP, SOX2 and SOX9 between genotypes. F. Graph of quantification 819 
of SOX2+ cells as a percentage of total nuclei in control and YAP-TetO pituitaries at 820 
P42 P=0.0014 (**); P63 P=0.0044 (**); P105 P<0.0001(****) (n=3 pituitaries per 821 
genotype). Following the Recovery treatment scheme in D, there is no significant 822 
difference in the numbers of SOX2+ cells between genotypes. G. Schematic outlining 823 
the time course of tamoxifen induction and doxycycline (DOX) treatment 824 
administered to Sox2CreERT2/+;R26rtTA/mTmG;Col1a1tetO-Yap/+ (mutant) and 825 
Sox2CreERT2/+;R26mTmG/+;Col1a1+/+ (control) animals to drive expression of YAP-826 
S127A in SOX2+ cells of mutants. H. Lineage tracing of SOX2+ cells and 827 
immunofluorescence staining against SOX2 and GFP shows an expansion of GFP+ 828 
cells compared to controls at P63, where a proportion of cells are double-labelled. I. 829 
Immunofluorescence staining against commitment markers PIT1, SF1 and terminal 830 
differentiation marker ACTH (TPIT lineage) together with antibodies against GFP 831 
detects double-labelled cells (arrows) across all three lineages in 832 
Sox2CreERT2/+;R26rtTA/mTmG;Col1a1tetO-Yap/+ pituitaries following the recovery period. 833 
Graph of quantification of GFP+;PIT1+, GFP+;SF1+ and GFP+;ACTH+ cells as a 834 
percentage of total GFP+ cells in Sox2CreERT2/+;R26rtTA/mTmG;Col1a1tetO-Yap/+ pituitaries 835 
at P63. Scale bars 100µm. Data in C. and F. represented as mean ± SEM, analysed 836 
with Two-Way ANOVA with Sidak’s multiple comparisons. See also figure 837 
supplement 1. 838 
 839 
Figure 6 Model of stem cell activity following regulation by the LATS/YAP/TAZ 840 
cascade in the anterior pituitary. 841 
SOX2+ pituitary stem cells express YAP and TAZ (green spheres). During normal 842 
developmental and postnatal expansion (normal regulation), pituitary stem cells are 843 
maintained as a balanced pool while generating endocrine cells of three committed 844 
lineages (red, blue, yellow). Expression of constitutively active YAP-S127A in 845 
pituitary stem cells leads to an elevation in target gene expression, an expansion of 846 
pituitary stem cell numbers and maintenance of the SOX+ state, preventing lineage 847 
commitment.  When YAP-S127A expression ceases, commitment into the endocrine 848 
lineages takes place. Genetic deletion of LATS kinases (LATS1 as well as one or two 849 
copies of LATS2), results in YAP and TAZ accumulation, major elevation in target 850 
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gene expression, repression of lineage commitment, continued expansion of SOX2+ 851 
cells and tumour formation.  852 
 853 
 854 
 855 
FIGURE  SUPPLEMENT LEGENDS 856 
 857 
Figure 1 – figure supplement 1 Regulation of YAP and TAZ during pituitary 858 
development. 859 
A. Hematoxylin and eosin staining on frontal sections through the pituitary from 860 
control and YAP-TetO heads after DOX treatment from 5.5dpc until 15.5dpc. B. 861 
Schematic outlining the time course of doxycycline (DOX) treatment administered to 862 
Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ (YAP-TetO) and Hesx1+/+;R26rtTA/+;Col1a1tetO-863 
Yap/+ controls to drive expression of YAP-S127A in mutant pituitaries during 864 
embryonic as well as postnatal development. C. Hematoxylin and eosin (H&E) 865 
staining of control and YAP-TetO pituitaries at P24. Higher magnification images 866 
show the presence of cysts in the YAP-TetO mutant. White arrows indicate cells with 867 
enlarged nuclei surrounding the cysts and yellow arrows indicate ciliated cells. D. 868 
Immunofluorescence staining against total YAP on frontal sections at P24 confirms 869 
accumulation of YAP protein in YAP-TetO compared to control sections, especially 870 
in the ventral anterior lobe. Immunofluorescence staining against SOX2 shows an 871 
expansion of SOX2+ epithelia lining cysts. E. Immunofluorescence staining for 872 
lineage-committed progenitor markers PIT1, TPIT and of ACTH marking the SF1 873 
lineage in control and YAP-TetO sections at P24. The number of SOX2+ and lineage-874 
committed cells is quantified in the graph below. Note there is a significant increase 875 
in the proportion of SOX2+ cells in YAP-TetO mutants (Student’s t-test, P<0.0001 876 
(****)), decrease in PIT1+ cells (Student’s t-test, P<0.0002 (***)), increase in SF1+ 877 
cells (Student’s t-test, P<0.0066 (**)) and no significant change in ACTH+ cells. F. 878 
Immunofluorescence staining against Ki-67 marking cycling cells in control and 879 
YAP-TetO sections at P24. Graph showing the percentage of Ki-67+ cells across total 880 
anterior pituitary cells. There is a trend towards a reduction in the proportion of 881 
cycling cells in YAP-TetO mutants, which is not significant (Student’s t-test, 882 
P>0.05). G. Immunohistochemistry using antibodies against p63 and the AE1/AE3 883 
cytokeratin cocktail in YAP-TetO mutants at P24 revealing positive cells lining the 884 
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cysts (arrowheads). H. Immunofluorescence staining using antibodies against 885 
ARL13B and Acetylated D-Tubulin, staining components of cilia, reveals ciliated 886 
cells lining the cysts. Staining for Alcian Blue and Period Acid Schiff (AB/PAS) to 887 
differentiate between acidic and neutral mucins reveals royal blue-stained mucous 888 
cells lining the cysts. Scale bars 1mm in A, 500µm in C and 100µm in magnified 889 
panels in C, 100µm in D, E, F and 50µm in G and H. 890 
 891 
Figure 1 – figure supplement 2 Regulation of YAP and TAZ during pituitary 892 
development. 893 
A. Hematoxylin and eosin staining on sagittal pituitary sections of 13.5dpc 894 
Hesx1Cre/+;Yapfl/fl;Taz-/- (mutant) and Hesx1+/+;Yapfl/+;Taz+/- (control) showing 895 
comparable morphology. B. Immunofluorescence staining using antibodies against 896 
SOX2 in Hesx1Cre/+;Yapfl/fl;Taz-/- and control at 13.5dpc (sagittal) and 16.5dpc 897 
(frontal) showing the presence of SOX2+ cells in both genotypes. C. 898 
Immunofluorescence staining for SOX2, Endomucin (EMCN) and active YAP in P28 899 
Hesx1Cre/+;Yapfl/fl;Taz-/- and control pituitaries, identifies SOX2+ cells in regions that 900 
are negative for active YAP (mice are null for TAZ) and normal vasculature. D. 901 
Graph quantifying the percentage of SOX2+ cells expressing active YAP in control 902 
and Hesx1Cre/+;Yapfl/fl;Taz-/- mutant pituitaries at P28. There is a reduction in double-903 
positive cells in the mutant, which did not reach significance.  E. 904 
Immunofluorescence staining for lineage committed progenitor markers PIT1 and 905 
SF1, as well as ACTH marking corticotrophs (TPIT lineage), reveals the presence and 906 
normal localisation of cells from the three lineages in a P28 Hesx1Cre/+;Yapfl/fl;Taz-/- 907 
mutant. Scale bars 100µm.  908 
 909 
Figure 2 – figure supplement 1 Pituitary-specific loss of Stk3 and Stk4 does not 910 
affect SOX2 cell specification or lineage commitment. 911 
A. Dorsal view of wholemount Hesx1Cre/+;Stk3fl/fl;Stk4fl/fl (mutant) and Stk3fl/fl;Stk4fl/fl 912 
(control) pituitaries at P0 showing comparable morphology and size at birth. B. 913 
Western blot to determine levels of STK3 and STK4 proteins in 914 
Hesx1Cre/+;Stk3fl/fl;Stk4fl/fl mutant pituitaries compared to controls at P35, using an 915 
antibody against total STK3 and STK4 proteins. Comparison of STK3/4 band 916 
intensities confirms a significant reduction in mutants (Student’s t-test, P=0.00032 917 
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(***)). STK3/4 bands normalised to the housekeeping protein Cyclophilin B. C. 918 
Immunofluorescence staining using antibodies against SOX2, TAZ, Endomucin 919 
(EMCN), YAP and pYAP at P0, indicating comparable staining between control and 920 
mutant samples. D. Immunofluorescence staining against lineage commitment 921 
markers PIT1, TPIT and SF1 shows normal lineage commitment in a 922 
Hesx1Cre/+;Stk3fl/fl;Stk4fl/fl  mutant pituitary compared to the control at P10. E. 923 
Hematoxylin and eosin staining through frontal sections of Hesx1Cre/+;Stk3fl/fl;Stk4fl/fl  924 
and control pituitaries at P70. AL: anterior lobe, IL: intermediate lobe, PL: posterior 925 
lobe. Scale bars 100µm. 926 
 927 
Figure 2 – figure supplement 2 Isolated deletions of Lats1 or Lats2 in the 928 
pituitary do not affect development. 929 
A. Hematoxylin and eosin staining of a sagittal section of Hesx1Cre/+;Lats1fl/fl at 930 
13.5dpc showing normal morphology (see Figure 2A for control). Dashed lines 931 
demarcate developing Rathke’s pouch. Immunofluorescence staining for TAZ and 932 
YAP reveals a normal expression pattern and no gross protein accumulation (compare 933 
to control, Figure 2A) B. Dorsal view of wholemount Hesx1Cre/+;Lats1fl/fl (mutant) and 934 
Hesx1Cre/+ (control) pituitaries at P0 showing comparable morphology and size at 935 
birth. C. RNAscope mRNA in situ hybridisation against Lats2 shows an increase in 936 
transcripts in the anterior pituitary following deletion of Lats1 (Hesx1Cre/+;Lats1fl/fl) 937 
compared to control (Hesx1Cre/+), where Lats2 expression is barely detectable. D. 938 
Hematoxylin and eosin staining of a sagittal section of Hesx1Cre/+;Lats2fl/fl at 13.5dpc 939 
showing normal morphology (see Figure 2A for control). Dashed lines demarcate 940 
developing Rathke’s pouch. E. Hematoxylin and eosin staining on frontal sections 941 
through 15.5dpc embryonic heads of Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl (mutant) and control 942 
(Hesx1+/+;Lats1fl/fl;Lats2fl/fl) genotypes, at the levels indicated in the cartoon. Note the 943 
hyperplastic pituitary at both axial levels, exerting mass effect on the brain. Asterisk 944 
indicates necrosis. Graph showing quantification of pituitary size at 15.5dpc as 945 
measured by the area occupied by the pituitary in matched histological sections 946 
between control and mutant embryos. Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl mutant pituitaries 947 
are significantly larger (average 0.7195mm2) compared to controls (average 948 
0.1994mm2) (Student’s t-test, P=0.0003 (***)). F. Quantification of Ki-67+ and 949 
SOX9+ cells across the whole Rathke’s pouch of Hesx1Cre/+ (control) and 950 
Hesx1Cre/+;Lats1fl/fl (mutant) pituitaries at 13.5dpc. There is a significant increase in 951 
 44 
cycling cells in mutants, marked by Ki-67 (Student’s t-test, P=0.0067 (**)). The 952 
proportion of SOX9+ cells is comparable between genotypes. Scale bars 100µm in A-953 
D, 1mm in E.  954 
 955 
Figure 3 – figure supplement 1 Analysis of tumourigenic lesions in postnatal 956 
pituitaries following pituitary-specific deletion of Lats1.  957 
A. Immunofluorescence staining for TAZ and active YAP reveal lesions of 958 
accumulation at P21 in Hesx1Cre/+;Lats1fl/fl;Lats2fl/+compared to 959 
Hesx1+/+;Lats1fl/fl;Lats2fl/+control. Immunofluorescence staining using antibodies 960 
against SOX2 and Endomucin (EMCN) show these lesions are composed of SOX+ 961 
stem cells and have reduced vascularisation. B. Hematoxylin and eosin staining of 962 
frontal sections from Hesx1Cre/+;Lats2fl/fl and Hesx1Cre/+ control pituitaries at P56 963 
showing comparable histology. C. Immunofluorescence staining against SOX2 and 964 
Endomucin on an intermediate lobe lesion (asterisk) in a Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ 965 
pituitary compared to control. D. Immunofluorescence staining against DNA damage 966 
marker gamma H2A.X showing positive cells in Hesx1Cre/+;Lats1fl/fl;Lats2fl/+mutants. 967 
E. P56 Immunohistochemistry using antibodies against p63 and the AE1/AE3 968 
cytokeratin cocktail, both positive in pituitary carcinomas, showing abundant staining 969 
in Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ compared to control. Note that membrane staining 970 
detected in controls is background for both antibodies. F. Immunohistochemistry 971 
using antibodies against synaptophysin, neural-specific enolase (NSE) and 972 
chromogranin demonstrate tumourigenic lesions in Hesx1Cre/+;Lats1fl/fl;Lats2fl/+ are 973 
negative for adenoma markers. Lesions are negative for vimentin by 974 
immunofluorescence staining, commonly marking spindle-cell oncocytoma in the 975 
pituitary. Scale bars 100µm in A, C-F; 500µm in B. PL: posterior lobe, IL: 976 
intermediate lobe, AL: anterior lobe. 977 
 978 
Figure 4 – figure supplement 1 Analysis of tumourigenic lesions in postnatal 979 
pituitaries following SOX2-specific deletion of Lats1. 980 
A. Graph of quantification of lineage commitment markers PIT1, TPIT and SF1, as a 981 
percentage of all anterior pituitary cells, in Sox2+/+;Lats1fl/fl;Lats2fl/+ (control) and 982 
Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ (mutant) pituitaries. There is a significant reduction in 983 
the percentage of committed cells of all three lineages in mutants compared to 984 
controls (Student’s t-test; PIT1: P<0.0001 (****), TPIT: P<0.0001 (****), SF1: 985 
 45 
P=0.004 (**)).  B. Immunohistochemistry using specific antibodies against p63 and 986 
cytokeratin cocktail AE1/AE3 on frontal sections of Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ 987 
(mutant) and Sox2+/+;Lats1fl/fl;Lats2fl/+ (control) pituitaries at P35, revealing positive 988 
staining in mutants. Note that the membrane staining in controls is background for 989 
both antibodies. C. Double immunofluorescence staining against total YAP and GFP, 990 
as well as SOX2 and GFP in consecutive sections of a tumourigenic lesion from 991 
Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+;R26mTmG/+ pituitaries at P35. Lineage tracing of 992 
SOX2+ cells, detected using GFP reveals abundant staining in the tumour lesion, 993 
characterised by accumulation of YAP and SOX2+ cells (yellow arrowheads). Scale 994 
bars 100µm. 995 
 996 
Figure 5 – figure supplement 1 Postnatal expression of constitutively active YAP 997 
increases leads to an activation of SOX2+ pituitary stem cells. 998 
A. Schematic outlining the time course of doxycycline (DOX) treatment administered 999 
to Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ (YAP-TetO) and Hesx1+/+;R26rtTA/+;Col1a1tetO-1000 
Yap/+ controls to drive expression of YAP-S127A in mutant pituitaries. Hematoxylin 1001 
and eosin staining of control and YAP-TetO pituitaries at P42 (3 weeks treatment), 1002 
P63 (6 weeks treatment) and P105 (12 weeks treatment). B. RNAscope mRNA in situ 1003 
hybridisation against YAP targets Cyr61 and Ctgf showing increased transcripts in 1004 
YAP-TetO sections compared to controls at P42. C. Analysis of YAP-TetO mutants 1005 
at P105: double immunofluorescence staining against SOX2 and Ki-67 reveals 1006 
regions of expanded SOX2+;Ki-67- cells compared to the normal expression pattern 1007 
in the control. This region is SOX9+, does not accumulate TAZ or YAP and 1008 
expresses pYAP as does normal anterior pituitary epithelium. Immunofluorescence 1009 
against PIT1 shows the absence of commitment to this lineage, a pattern not seen in 1010 
the control. Hematoxylin and eosin staining in consecutive sections identifies this 1011 
region, which does not have neoplastic features. D. Schematic outlining the time 1012 
course of doxycycline (DOX) treatment administered to 1013 
Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ (YAP-TetO) and Hesx1+/+;R26rtTA/+;Col1a1tetO-1014 
Yap/+ controls to drive expression of YAP-S127A in mutant pituitaries for three weeks, 1015 
followed by a three-week recovery period in the absence of DOX. Hematoxylin and 1016 
eosin staining of control and YAP-TetO pituitaries. RNAscope mRNA in situ 1017 
hybridisation shows comparable levels of expression of targets Cyr61 and Ctgf. E. 1018 
Graph comparing total fluorescence of Cyr61 and Ctgf by Fast Red RNAscope 1019 
 46 
mRNA in situ hybridisation across sections from control, 1020 
Hesx1Cre/+;R26rtTA/+;Col1a1tetO-Yap/+ (YAP-TetO) and Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ 1021 
anterior pituitaries, normalised for total anterior pituitary area. There is a significant 1022 
increase in the expression of both targets in Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+ pituitaries 1023 
compared to other genotypes (one-way ANOVA with Tukey’s post hoc test; Control 1024 
v Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+: P<0.0001 for Cyr61 (****), P=0.001 for Ctgf (***); 1025 
YAP-TetO v Sox2CreERT2/+;Lats1fl/fl;Lats2fl/+: P<0.0001 for Cyr61 (****), P=0.0049 1026 
for Ctgf (**)). Scale bars 250µm in A, 100µm in B-D. 1027 
 1028 
SUPPLEMENTARY FILE LEGENDS 1029 
 1030 
Supplementary File 1 1031 
Table showing expected and observed frequency of genotypes from 1032 
Hesx1Cre/+;Yapfl/fl;Taz+/-  x Yapfl/fl;Taz+/- at embryonic 15.5dpc and postnatal day 0-2. 1033 
Embryonic: P=0.3471, Chi-square test (two tailed). Postnatal: P=0.0003 (***), Chi-1034 
square test (two tailed). 1035 
 1036 
Supplementary File 2 1037 
Table showing expected and observed frequency of genotypes from 1038 
Hesx1Cre/+;Lats1fl/+;Lats2fl/+ x Lats1fl/fl;Lats2fl/fl and Hesx1Cre/+;Lats1fl/+;Lats2fl/+ x 1039 
Lats1fl/fl;Lats2fl/+ at embryonic 15.5dpc and postnatal day 0-2. Embryonic: P<0.0001 1040 
(****), Chi-square test (two tailed). Postnatal: P<0.0001 (****), Chi-square test (two 1041 
tailed). 1042 
 1043 
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